Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-16 4:11 pm Purchase | 13G | KALA BIO, INC. KALA | MILLENNIUM MANAGEMENT LLC | 135,096 5% | 135,096 (New Position) | View |
| 2024-02-14 4:21 pm Purchase | 13G | KALA BIO, INC. KALA | BAKER BROS. ADVISORS LP | 269,213 9.99% | 88,300 (+48.81%) | View |
| 2024-02-14 1:09 pm Sale | 13G | KALA BIO, INC. KALA | Checkpoint Capital L.P. | 0 0% | -228,032 (Position Closed) | View |
| 2024-01-29 4:36 pm Sale | 13G | KALA BIO, INC. KALA | INTEGRATED CORE STRATEGIES (US) LLC | 132,674 4.9% | -1,029 (-0.77%) | View |
| 2023-10-18 4:04 pm Unchanged | 13D | KALA PHARMACEUTICALS INC KALA | Longitude Capital Partners II LLC | 108,239 4.3% | 0 (Unchanged) | View |
| 2023-06-15 11:57 am Purchase | 13G | KALA BIO, INC. KALA | Checkpoint Capital L.P. | 228,032 9.7% | 228,032 (New Position) | View |
| 2023-02-14 4:15 pm Sale | 13D | KALA PHARMACEUTICALS INC KALA | Longitude Capital Partners II LLC | 108,239 6.3% | -5,348,791 (-98.02%) | View |
| 2023-02-14 4:00 pm Purchase | 13G | KALA BIO, INC. KALA | BAKER BROS. ADVISORS LP | 180,913 9.99% | 180,913 (New Position) | View |
| 2023-01-17 4:38 pm Purchase | 13G | KALA BIO, INC. KALA | INTEGRATED CORE STRATEGIES (US) LLC | 133,703 8.4% | 133,703 (New Position) | View |
| 2022-06-03 5:11 pm Sale | 13D | KALA PHARMACEUTICALS INC KALA | RA CAPITAL MANAGEMENT L.P. | 3,412,868 4.7% | -2,781,921 (-44.91%) | View |
| 2022-05-31 5:31 pm Sale | 13D | KALA PHARMACEUTICALS INC KALA | RA CAPITAL MANAGEMENT L.P. | 6,194,789 8.53% | -1,850,510 (-23.00%) | View |
| 2022-05-25 5:12 pm Sale | 13D | KALA PHARMACEUTICALS INC KALA | RA CAPITAL MANAGEMENT L.P. | 8,045,299 11.08% | -2,869,314 (-26.29%) | View |
| 2022-04-01 4:30 pm Sale | 13D | KALA PHARMACEUTICALS INC KALA | RA CAPITAL MANAGEMENT L.P. | 10,914,613 15.03% | -46,920 (-0.43%) | View |
| 2022-02-14 11:50 am Sale | 13G | KALA PHARMACEUTICALS INC KALA | EVENTIDE ASSET MANAGEMENT LLC | 0 0% | -3,450,000 (Position Closed) | View |
| 2022-01-10 12:54 pm Sale | 13G | KALA PHARMACEUTICALS INC KALA | BlackRock Inc. BLK | 3,134,773 4.8% | -25,733 (-0.81%) | View |
| 2021-11-26 4:17 pm Purchase | 13D | KALA PHARMACEUTICALS INC KALA | Lagunita LLC | 5,341,120 7.3% | 5,341,120 (New Position) | View |
| 2021-11-26 4:16 pm Purchase | 13D | KALA PHARMACEUTICALS INC KALA | Lagunita Biosciences LLC | 5,341,120 7.3% | 5,341,120 (New Position) | View |
| 2021-11-24 2:27 pm Purchase | 13D | KALA PHARMACEUTICALS INC KALA | Blumenkranz Mark S. | 5,341,120 7.3% | 5,341,120 (New Position) | View |
| 2021-10-28 4:23 pm Purchase | 13D | KALA PHARMACEUTICALS INC KALA | RA CAPITAL MANAGEMENT L.P. | 10,961,533 16.85% | 86,920 (+0.80%) | View |
| 2021-10-14 5:00 pm Sale | 13G | KALA PHARMACEUTICALS INC KALA | ORBIMED ADVISORS LLC | 0 0% | -4,714,195 (Position Closed) | View |